Skip to Main Content

Paper Details

Evaluation of musculoskeletal phenotype of the G608G progeria mouse model with lonafarnib, pravastatin, and zoledronic acid as treatment groups.
Proc Natl Acad Sci U S A
16
2020
BAC, Cartilage abnormalities, G608G, HGPS, HGPS G608G, Hutchinson-Gilford progeria syndrome, Lonafarnib, degenerative joint diseases, lonafarnib, mice, mouse, pravastatin, progeria, skeletal dysplasia, zoledronic acid
Author NameAffiliation
Michael R ErdosMedical Genomics and Metabolic Genetics Branch of the National Human Genome Research Institute, National Institutes of Health
Michael R ErdosMedical Genomics and Metabolic Genetics Branch of the National Human Genome Research Institute, National Institutes of Health
Francis S CollinsMedical Genomics and Metabolic Genetics Branch of the National Human Genome Research Institute, National Institutes of Health
Francis S CollinsMedical Genomics and Metabolic Genetics Branch of the National Human Genome Research Institute, National Institutes of Health
Brian D SnyderCenter for Advanced Orthopaedic Studies, Beth Israel Deaconess Medical Center
Brian D SnyderBoston Children's Hospital
  • 1 - 6

Datasets

Release 1.2